Australia Health

Telix Pharmaceuticals (ASX:TLX) received official approval from the U.S. Food and Drug Administration for its brain cancer imaging agent Pixclara.

Immutep (ASX:IMM) has contracted a new 200-litre manufacturing run of eftilagimod alfa following the early discontinuation of its TACTI-004 clinical study.

Optiscan Imaging (ASX:OIL) imaged over 80 cases using its InForm platform in a live digital pathology study conducted with Australian Clinical Labs.

Lenders for Healthscope have extended a crucial vote by 24 hours to decide on a takeover offer exceeding $400 million for 27 hospital sites.

Biome Australia (ASX:BIO) announced it will launch Biome Daily Probiotic 60 and Biome Daily Kids Probiotic 60 in the first half of FY27.

Neurizon Therapeutics (ASX:NUZ) announced that the US National Institutes of Health awarded a multi-year grant.

Osteopore (ASX:OSX) secured market access in Thailand for its complete line of orthopaedic products.

Mental health care provider Emyria (ASX:EMD) completed key operational milestones to open its first Sydney clinic in September.

OncoSil Medical (ASX:OSL) has secured $5.6 million in total commitments through a share placement.

Dimerix (ASX:DXB) has entered into an agreement for a $34 million non-dilutive facility to fund its upcoming clinical trial milestones.

Memphasys (ASX:MEM) secured product registration in Turkey for its Felix System, enabling the immediate commencement of commercial sales.

Regis Healthcare (ASX:REG) stated that a 2.55% government funding increase to $303.19 per day falls well below cost inflation.